Evaluation of Histone Deacetylase Inhibitors as Therapeutics for Neurodegenerative Diseases

Various neurodegenerative diseases are associated with aberrant gene expression. We recently identified a novel class of pimelic o -aminobenzamide histone deacetylase (HDAC) inhibitors that show promise as therapeutics in the neurodegenerative diseases Friedreich’s ataxia (FRDA) and Huntington’s disease (HD). Here, we describe the various techniques used in our laboratories to dissect mechanisms of gene silencing in FRDA and HD, and to test our HDAC inhibitors for their ability to reverse changes in gene expression in cellular models.